CTRI/2009/091/000824已完成2 期
A randomised, double-blind, placebo-controlled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type 2 diabetes mellitus and insufficient glycaemic control
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 451
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Diagnosis of type 2 diabetes mellitus prior to informed consent.
- •2. Male and female patients, currently treated with metformin alone, or with metformin and not more than one other oral antidiabetic drug (antidiabetic therapy may be a sulphonylurea, meglitinide, DPP-4 inhibitor or α-glucosidase inhibitor and its dose has to be unchanged for 12 weeks prior to informed consent).
- •A total daily dose of ≥1500 mg/day metformin divided into twice daily administration (e.g., 850 mg bid, 1000 mg bid, 850/1000 mg bid or 500/1000 mg bid) is required for inclusion into the trial. A patient taking metformin tid can be included if switched to a bid dosing regimen at the time of informed consent. In this case, the total daily dose must be maintained (e.g., 500 mg tid to 1000/500 mg bid, 1000/500/500 mg tid to 1000 bid, 500/500/850 mg tid to 1000/850 mg bid). Patients treated with a total daily dose of metformin of less than 1500 mg (e.g., 500 mg bid) can be included in the trial only if the Investigator has documented that the dose is the maximum tolerated dose for that patient.
- •The total daily dosage of metformin needs to be stable for at least 12 weeks prior to randomisation and throughout the duration of the study.
- •3. Glycosylated haemoglobin A1 (HbA1c) at Visit 1a (Screening) fulfils the following
- •- For patients undergoing wash out of previous medication: ≥7.0 % to ≤9.5 %..
- •- For patients not undergoing wash-out of previous medication: ≥7.0% to ≤10.0%.
- •4. Glycosylated haemoglobin A1 (HbA1c) ≥7.0 to ≤10.0% at Visit 2 (Start of Run-in).
- •5. Age ≥18 and ≤80 years at Visit 1a (Screening).
- •6. BMI ≤45 kg/m2 (Body Mass Index) at Visit 1a (Screening).
- •7. Signed and dated written informed consent by date of Visit 1a in accordance with
- •GCP and local legislation.
排除标准
- •1. Treatment with extended release formulations of metformin within 12 weeks prior to consent.
- •2. Uncontrolled hyperglycaemia with a glucose level 240 mg/dL (13.3 mmol/L) after an overnight fast during wash-out/placebo run-in and confirmed by a second measurement (not on the same day).
- •3. Myocardial infarction, stroke or TIA within 6 months prior to informed consent.
- •4. Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1a.
- •5. Gastric bypass surgery.
- •6. Known hypersensitivity or allergy to the investigational product or its excipients or to the trial background therapy (i.e., metformin).
- •7. Contraindication to metformin therapy according to local label, for example:
- •? Renal disease or renal dysfunction (e.g., as specified by product information
- •of locally approved metformin)
- •? Dehydration by clinical judgement of the investigator
- •? Acute or chronic metabolic acidosis (present condition in patient history)
- •? Hereditary galactose intolerance.
- •8. Renal failure or renal impairment (serum creatinine ≥1.5 mg/dL [132 μmol/L]) as
- •determined at Visit 1a (Screening).
- •9. Treatment with rosiglitazone, pioglitazone, GLP-1 analogues/mimetics or insulin
- •within 3 months prior to informed consent.
- •10. Treatment with anti-obesity drugs (e.g., sibutramine, orlistat, rimonabant) 3 months
- •prior to informed consent.
- •11. Alcohol or drug abuse within the 3 months prior to informed consent that would
- •interfere with trial participation.
- •12. Current treatment with systemic steroids at time of informed consent or change in
- •dosage of thyroid hormones within 6 weeks prior to informed consent. However, the
- •use of inhaled steroids (e.g., for asthma, COPD) is not an exclusion as these do not
- •cause systemic steroid action.
- •13. Participation in another trial with an investigational drug within 2 months prior to
- •informed consent.
- •14. Pre-menopausal women (last menstruation ≤1 year prior to informed consent) who:
- •? are nursing or pregnant or
- •? are of child-bearing potential and are not practicing an acceptable method of
- •birth control, or do not plan to continue using this method throughout the
- •study and do not agree to submit to periodic pregnancy testing during
- •participation in the trial. Acceptable methods of birth control include
- •transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral,
- •implantable or injectable contraceptives, sexual abstinence and vasectomised
- •partner. No exception will be made.
研究者
相似试验
进行中（未招募）
不适用
The effect of an intranasal antihistamine/steroid combination product for the treatment of allergic rhinitis utilising an allergen Environmental Challenge ChamberAllergic rhinitis (AR) in its seasonal and perennial form is a common allergic condition. It is clinically defined as a symptomatic disorder induced by immunoglobulin E (IgE)-mediated inflammation after allergen exposure to mucous membranes of the nose.EUCTR2013-002940-94-ATGlaxoSmithKline
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type 2 diabetes mellitus and insufficient glycaemic control - NDtype 2 diabetes mellitusMedDRA version: 12.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-013549-27-ITBOEHRINGER ING.900
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic rhinitisseasonal allergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10039776Term: Seasonal allergic rhinitisEUCTR2008-001567-10-DEGlaxoSmithKline Research & Development Limited54
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthmaMild asthmaMedDRA version: 9.1Level: LLTClassification code 10001705Term: Allergic asthmaEUCTR2008-005205-19-GBGlaxoSmithKline Research & Development Limited
进行中（未招募）
1 期
A 2 part clinical study that will evaluate the safety and effectiveness of LJN452A to treat patients with fatty liver disease for a period of 12 weeks. The first part will be used for LJN452 dose selection for the second part of the study.on-alcoholic Steatohepatitis (NASH)MedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2015-005215-33-SKovartis Pharma Services AG345